|Product:||ProCervix® The vaccine is composed of two recombinant Adenylate Cyclase proteins (CyaA) in equal parts.|
|Disease:||Prevention of cervical cancer in patients already infected with human papillomavirus (HPV)|
|Other:||Genticel has received clearance to start a Phase I clinical trial with its candidate therapeutic vaccine, ProCervix®, aimed at preventing cervical cancer in patients already infected with HPV (HPV16 or HPV18 virus strains).
The clinical trial will take place in Belgium starting Q3 2010, at the Centre for the Evaluation of Vaccinations in the Vaccine & Infectious Disease Institute of the University of Antwerp, under the direction of Professor Pierre Van Damme. The key objectives are to evaluate the safety and immunogenicity of ProCervix®.